Navigation Links
FDA Issues Warnings to Marketers of Unapproved 'Chelation' Products
Date:10/14/2010

SILVER SPRING, Md., Oct. 14 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today warned eight companies that their over-the-counter (OTC) chelation products are unapproved drugs and devices and that it is a violation of federal law to make unproven claims about these products. There are no FDA-approved OTC chelation products.

(Logo:  http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

The companies that received the warning letters claim that their products treat a range of diseases by removing toxic metals from the body. Some also claim to treat autism spectrum disorder, cardiovascular diseases, Parkinson's disease, Alzheimer's disease, macular degeneration, and other serious conditions. Some companies that received the warning letters also claim their products will detect the presence of heavy metals to justify the need for chelation therapy.

The drug products involved have not been evaluated by the FDA for treatment of these diseases, and violate the Federal Food, Drug, and Cosmetic Act (FFDCA). Despite the claims of the companies that received warning letters, the effectiveness in treating any of the diseases listed is unsubstantiated. Depending on the condition, when relying on unproven OTC chelation products to treat serious conditions, patients may delay seeking effective medical care.

In addition, there are serious safety issues associated with chelation products, which can alter the levels of certain substances in the blood.  Even when used under medical supervision, these products can cause serious harm, including dehydration, kidney failure, and death.  

"These products are dangerously misleading because they are targeted to patients with serious conditions and limited treatment op
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
2. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
3. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
4. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
5. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
6. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Bioniche Life Sciences Inc.
8. Lupus Under the Spotlight: U.S. Congress Shows Support for Womens Health Issues
9. European Unions CHMP Issues Positive Opinion on Sugammadex
10. Newly Published Study Shows OPKOs siRNA Bevasiranib Is Taken Up by Target Tissues in the Eye
11. Ending Cervical Cancer Featured at Summit; QIAGEN CEO Issues a Call to Global Women Leaders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Valeritas, Inc., ... designed for patients with Type 2 diabetes, announced today ... Chain Excellence Award. The award was presented October 16 ... Columbus, Ohio . ... judged across a variety of metrics specifically targeted at ...
(Date:10/20/2014)... , Oct. 20, 2014 Lpath, ... leader in bioactive lipid-targeted therapeutics, received official notification from ... been granted another key patent supporting its iSONEP™ ... issued patent, European patent No. 2087002, claims compositions ... in Lpath,s two lead compounds, iSONEP and ASONEP. ...
(Date:10/20/2014)... YORK and RALEIGH, N.C., Oct. 20, 2014 ... Hereditary Neuropathy Foundation (HNF), both philanthropies, announced today ... drug candidates for the treatment of the rare ... BioPontis Alliance announced its alliance model earlier ... a first demonstration of a collaborative model where ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3
... 5, 2012  Orexigen ® Therapeutics, Inc. (Nasdaq: ... presenting at the 30th Annual J.P. Morgan Healthcare Conference in ... at 9:00 a.m. PST (12:00 p.m. EST). To listen to ... visit the Investor Relations section of the Company,s Web site ...
... , Company expects to meet or exceed ... and earnings declines due to Zyprexa patent expiration. , ... , Company expects to keep 2012 operating expenses essentially flat ... be in the range of $3.10 - $3.20. , ...
Cached Medicine Technology:Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 2Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 3Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 4Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance 5
(Date:10/20/2014)... IN (PRWEB) October 20, 2014 ... Start, a secure cloud solution that enables healthcare ... of the ultimate healthcare-specific customer relationship management (“CRM”) ... meet the unique needs of the healthcare industry, ... experience for providers and patients by combining healthcare ...
(Date:10/20/2014)... Diego, CA (PRWEB) October 20, 2014 AttorneyOne.com, ... all the latest information from the FDA on Sit ... on October 10 not to purchase or use Sit and ... Sit and Slim II is promoted as weight loss product ... Sibutramine, removed from the market in 2010 for safety reasons, ...
(Date:10/20/2014)... 2014 National Teen Driver Safety Week is ... Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ) is joining ... of teen drivers to talk to their teens and always ... vehicle crashes are the leading cause of death for U.S. ... fatal crashes, and 859 (42%) of those teen drivers were ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher Patronella ... innovative True Form Tummy Tuck® method as ... at The University of Texas Medical Branch in ... medical student. Patronella, who is a founding partner of ... in Texas, The Aesthetic Center for Plastic Surgery ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Dr. Babatunde ... Fund, welcomes news of a ceasefire agreement that is ... than 200 girls who were kidnapped from the north-eastern ... languished in captivity long enough, and it is high ... communities," stated Dr. Osotimehin. , "We owe it to ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
... N.C. , Jan. 19 Sodium consumption is a hot ... their recipes to find ways to have products that everyone can feel ... in sodium—40% to 70% less than table salt—and tastes good. , In ... salt. Total sales that year did not even reach $100.00 . ...
... , , ATLANTA , Jan. ... Director of the Unit of Interventional Radiology at the European ... Oncology 2010 Best Poster Award by Dr. Shaun Samuels ... Micro-Bland Embolization Combined with Radiofrequency Ablation for Treating Complex Hepatic ...
... Speaker Nancy Pelosi , House Majority Leader Steny ... availability this afternoon in the Capitol following a Democratic leadership meeting. Below ... , As you may be aware, we just had a meeting ... you,re aware of in Massachusetts and the rest, we,re still ...
... rationing health care, particularly at the end of life, may ... Johns Hopkins emeritus professor of neurology called for the start ... this month,s issue of the Journal of Medical Ethics ... Professor Emeritus of Pediatric Neurology and a faculty member of ...
... with spinal injuries, experts say , , TUESDAY, Jan. 19 ... were able to form proper brain connections in newborn mice, ... their study was the first to show that stem cells ... link correctly in the brain. The findings, they say, could ...
... The cholesterol drugs might reduce risk of infection, researchers find ... known as statins hold promise as a treatment for sickle ... , The findings, published Jan. 19 in the ... mice, so it,s not clear if humans with the disease ...
Cached Medicine News:Health News:Ocean's Flavor Natural Sea Salt is Helping Companies Reach Low Sodium Goals 2Health News:Ocean's Flavor Natural Sea Salt is Helping Companies Reach Low Sodium Goals 3Health News:Orsi Awarded First Place for Procedure with Embozene(TM) Microspheres 2Health News:Transcript of Pelosi, House Democratic Leaders' Press Availability Today Following Leadership Meeting 2Health News:Transcript of Pelosi, House Democratic Leaders' Press Availability Today Following Leadership Meeting 3Health News:Reasoning through the rationing of end-of-life care 2Health News:Stem Cells Become Functioning Neurons in Mice 2